Medtronic Affera Catheter Clinical Milestones
Analysis based on 8 articles · First reported Apr 25, 2026 · Last updated Apr 25, 2026
The positive clinical trial results and regulatory designation for Medtronic's cardiac arrhythmia treatment technologies are expected to boost investor confidence in Medtronic, potentially leading to an increase in its stock price. The advancements address a significant unmet medical need, which could expand Medtronic's market share in the medical device industry.
Medtronic announced significant clinical study milestones for its Affera family of technologies, including the Sphere-9 and Sphere-360 catheters, for cardiac arrhythmia treatment. Key data presented at the Heart Rhythm Society Annual Meeting showed 65.5% of patients treated with the Sphere-9 catheter for ventricular tachycardia (VT) remained recurrence-free at six months. The United States — Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for VT, expediting its regulatory pathway. Additionally, the Sphere-360 catheter demonstrated 100% lesion durability in AFib procedures in a European study, and Medtronic initiated the Conquer-AF trial for the Sphere-9 catheter in recurrent atrial fibrillation patients across the U.S., Europe, and Australia. These developments highlight Medtronic's commitment to advancing cardiac care.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard